Could a common diabetes drug protect transplanted kidneys?

NCT ID NCT04965935

Completed Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether dapagliflozin, a drug used for type 2 diabetes, can lower blood pressure in people who have received a kidney transplant. Fifty-two participants took either the drug or a placebo for 12 weeks. The goal was to see if the drug helps control blood pressure and blood sugar, which are important for keeping the transplanted kidney healthy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dapagliflozin (a diabetes drug that helps lower blood sugar and blood pressure)
What this could lead to: If successful, this could point toward a new way to manage blood pressure and diabetes in kidney transplant recipients, potentially improving long-term outcomes.
What could go wrong: This is a small, early-phase trial with only 52 participants, so results may not apply to everyone. The drug also carries risks like dehydration or infections in this vulnerable population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT RECIPIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANT RECIPIENTS POST TRANSPLANT DIABETES MELLITUS TYPE 2 DIABETES

Contacts and locations

Locations

Renal Physiology Laboratory

Toronto, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.